Metastatic Uveal Melanoma Pipeline Analysis: Emerging Targeted and Immunotherapeutic Approaches Transforming the Future of Metastatic Uveal Melanoma Treatment | DelveInsight

DelveInsight's Metastatic Uveal Melanoma Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline metastatic uveal melanoma therapies in various stages of clinical development. Major pharmaceutical and biotechnology companies are actively advancing innovative therapeutic strategies to address the high unmet need in metastatic uveal melanoma treatment.

Key takeaways from the Metastatic Uveal Melanoma Clinical Trial Landscape Report
• DelveInsight's metastatic uveal melanoma pipeline report depicts a growing therapeutic landscape with multiple active players developing promising therapies across different stages of clinical development.
• Key metastatic uveal melanoma companies such as IDEAYA Biosciences, Servier, Novartis, Replimune Inc., Iovance Biotherapeutics, Ionctura, and InxMed (Shanghai) Co., Ltd. are actively working to strengthen the metastatic uveal melanoma pipeline space.
• Promising metastatic uveal melanoma pipeline therapies in development include Darovasertib, DYP688, RP2, Roginolisib, IOV-3001, and IN10018.

Request a sample and discover the recent advances in metastatic uveal melanoma treatment drugs at https://www.delveinsight.com/sample-request/metastatic-uveal-melanoma-mum-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Metastatic Uveal Melanoma?
Metastatic uveal melanoma is an advanced form of uveal melanoma, a rare eye cancer originating from pigment-producing cells in the uveal tract, which includes the iris, ciliary body, and choroid. While primary uveal melanoma initially remains confined to the eye, nearly half of patients eventually develop metastatic disease, with the liver representing the most common site of metastasis, followed by the lungs and bones. Metastatic uveal melanoma is associated with poor prognosis due to limited effective treatment options and resistance to conventional chemotherapy and immunotherapy approaches. Current management strategies focus on systemic therapies, liver-directed interventions, and participation in clinical trials to improve patient outcomes and quality of life.

Emerging Metastatic Uveal Melanoma Drug Profiles

DYP688: Novartis
DYP688 is an investigational antibody-drug conjugate (ADC) administered intravenously that selectively targets metastatic uveal melanoma cells harboring activating GNAQ or GNA11 mutations. The therapy consists of an antibody directed against PMEL17 linked to a cytotoxic payload designed to inhibit oncogenic GNAQ/GNA11 signaling pathways responsible for tumor proliferation.
DYP688 is currently being evaluated in a Phase I/II clinical trial assessing safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with metastatic uveal melanoma and other GNAQ/11 mutant melanomas. Preliminary data demonstrated encouraging anti-tumor activity with favorable safety and tolerability profiles.

Darovasertib: IDEAYA Biosciences/Servier
Darovasertib is an investigational oral protein kinase C (PKC) inhibitor being developed by IDEAYA Biosciences in partnership with Servier for metastatic uveal melanoma. The therapy is currently in Phase II/III development and targets protein kinase C signaling pathways implicated in uveal melanoma progression.

Darovasertib is being evaluated both as monotherapy and in combination with crizotinib in registration-enabling studies for first-line metastatic uveal melanoma treatment.

Learn more about the novel and emerging metastatic uveal melanoma pipeline therapies at https://www.delveinsight.com/sample-request/metastatic-uveal-melanoma-mum-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Recent Developments in the Metastatic Uveal Melanoma Clinical Trial Landscape
• In December 2025, IDEAYA Biosciences announced completion of targeted enrollment of 435 patients in the registration-enabling Phase II/III OptimUM-02 trial evaluating darovasertib in combination with crizotinib for first-line HLA*A2-negative metastatic uveal melanoma. The company expects to report progression-free survival data in the first quarter of 2026 to support potential accelerated approval in the United States.
• In October 2025, IDEAYA Biosciences reported the first median overall survival results from the Phase I/II OptimUM-01 trial evaluating darovasertib in combination with crizotinib as a first-line treatment for metastatic uveal melanoma.
• In July 2022, Novartis initiated a Phase I/II multicenter study evaluating DYP688 in patients with metastatic uveal melanoma and other GNAQ/11 mutant melanomas.
• As of October 2024, preliminary clinical findings from DYP688 demonstrated confirmed objective responses, stable disease outcomes, and manageable adverse events in heavily pretreated metastatic uveal melanoma patients.

Scope of the Metastatic Uveal Melanoma Pipeline Report
• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase I/II, Phase II, Phase II/III
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Intratumoral
• Therapeutics Assessment By Molecule Type: Antibody-drug conjugates, Small molecules, Fusion proteins, Engineered HSV backbone therapies
• Key Metastatic Uveal Melanoma Companies: IDEAYA Biosciences, Servier, Novartis, Replimune Inc., Ionctura, Iovance Biotherapeutics, and InxMed (Shanghai) Co., Ltd.
• Key Metastatic Uveal Melanoma Pipeline Therapies: Darovasertib, DYP688, RP2, Roginolisib, IOV-3001, and IN10018.

Dive deep into rich insights for new drugs for metastatic uveal melanoma treatment, visit https://www.delveinsight.com/sample-request/metastatic-uveal-melanoma-mum-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents
1. Metastatic Uveal Melanoma Pipeline Report Introduction
2. Metastatic Uveal Melanoma Pipeline Report Executive Summary
3. Metastatic Uveal Melanoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Mid Stage Products (Phase II/III)
8. Mid Stage Products (Phase II)
9. Early Stage Products (Phase I/II)
10. Early Stage Products (Phase I)
11. Preclinical Stage Products
12. Collaborations Assessment
13. Inactive Products
14. Metastatic Uveal Melanoma Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Appendix

For further information on the metastatic uveal melanoma pipeline therapeutics, reach out at Metastatic Uveal Melanoma Pipeline Insights

Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.